Dr Christopher Guise

Biography

Research interests:

Selected publications and creative works (Research Outputs)

  • Li, X., Guise, C. P., Taghipouran, R., Yosaatmadja, Y., Ashoorzadeh, A., Paik, W.-K., ... Xu, Y. (2017). 2-Oxo-3, 4-dihydropyrimido[4, 5-d]pyrimidinyl derivatives as new irreversible pan fibroblast growth factor receptor (FGFR) inhibitors. European Journal of Medicinal Chemistry, 135, 531-543. 10.1016/j.ejmech.2017.04.049
    Other University of Auckland co-authors: Christopher Squire, Adam Patterson, Jeffrey Smaill, Amir Ashoorzadeh, Yuliana Yosaatmadja
  • Zygouropoulou, M., Kubiak, A. M., Copp, J. N., Dubois, L. J., Mowday, A. M., Guise, C. P., ... Patterson, A. V. (2017). Clostridium as "Trojan Horse" Vectors for Cancer Treatment. Paper presented at 20th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC. 10 May - 13 May 2017. MOLECULAR THERAPY. (pp. 1).
    Other University of Auckland co-authors: Jeffrey Smaill, Adam Patterson
  • Mowday, A. M., Guise, C. P., Kubiak, A. M., Minton, N. P., Abbattista, M. R., Lambin, P., ... Patterson, A. V. (2017). Efficacy of a Novel Enzyme/Prodrug Combination for Clostridia Directed Enzyme Prodrug Therapy. Paper presented at 20th Annual Meeting of the American-Society-of-Gene-and-Cell-Therapy (ASGCT), Washington, DC. 10 May - 13 May 2017. MOLECULAR THERAPY. (pp. 2).
    Other University of Auckland co-authors: Jeffrey Smaill, Adam Patterson
  • Guise, C., Abbattista, M., Mowday, A., Ashoorzadeh, A., Bull, M., Silva, S., ... Theys, J. (2017). SN36506: A rationally designed second generation analogue of PR-104 selected for clinical evaluation. Paper presented at 15th International Tumour Microenvironment Workshop, Miami, FL, USA. 27 April - 29 April 2017.
    Other University of Auckland co-authors: Maria Abbattista, Amir Ashoorzadeh, Bob Anderson, Jack Flanagan, Kevin Hicks, Jeffrey Smaill, Adam Patterson, Matthew Bull
  • Mo, C., Zhang, Z., Guise, C. P., Li, X., Luo, J., Tu, Z., ... Ren, X. (2017). 2-Aminopyrimidine derivatives as new selective Fibroblast Growth Factor Receptor 4 (FGFR4) inhibitors. ACS Medicinal Chemistry Letters, 8 (5), 543-548. 10.1021/acsmedchemlett.7b00091
    Other University of Auckland co-authors: Adam Patterson, Jeffrey Smaill
  • Copp, J. N., Mowday, A. M., Williams, E. M., Guise, C. P., Ashoorzadeh, A., Sharrock, A. V., ... Ackerley, D. F. (2017). Engineering a multifunctional nitroreductase for improved activation of prodrugs and PET probes for cancer gene therapy. Cell Chemical Biology, 24 (3), 391-403. 10.1016/j.chembiol.2017.02.005
    Other University of Auckland co-authors: Jeffrey Smaill, Amir Ashoorzadeh, Jack Flanagan, Adam Patterson
  • Mowday, A., Ashoorzadeh, A., Williams, E., Copp, J., Silva, S., Bull, M., ... Guise, C. (2016). Rational design of an AKR1C3-resistant analog of PR-104 for enzyme-prodrug therapy. Biochemical Pharmacology, 116, 176-187. 10.1016/j.bcp.2016.07.015
    URL: http://hdl.handle.net/2292/30209
    Other University of Auckland co-authors: Jack Flanagan, Adam Patterson, Bob Anderson, Jeffrey Smaill, Maria Abbattista, Amir Ashoorzadeh, Matthew Bull, Shevan Silva
  • Patterson, A. V., Kimple, R. J., Jackson, V. J., Swick, A. D., Guise, C. P., Abbattista, M. R., ... Sun, J. D. (2016). Development of biomarkers to guide the clinical development of tarloxotinib bromide, a hypoxia-activated irreversible EGFR/HER2 inhibitor.. Paper presented at Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, Illinois, USA. 3 June - 7 June 2016. Journal of Clinical Oncology. (pp. 3). 10.1200/JCO.2016.34.15_suppl.e17521
    Other University of Auckland co-authors: Jeffrey Smaill, Adam Patterson, Matthew Bull

Contact details

Primary office location

M&HS BUILDING 504 - Bldg 504
Level 0, Room 018
85 PARK RD
GRAFTON
AUCKLAND 1023
New Zealand